Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George’s University Hospitals NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. His particular research interests are in the epidemiology of vaccine preventable diseases, in clinical vaccine trials, particularly in at-risk groups and in perinatal infections.

He coordinates a European neonatal infection surveillance network (neonIN) and the UK Paediatric Vaccine Group (UKPVG), and other recent work includes national surveillance on neonatal meningitis, neonatal GBS and Listeria infections, maternal immunisation trials, studies of different vaccine schedules in preterm infants and COVID-19 vaccine trials (Phase I-III). He is Chair of the Research Committee of the European Society of Paediatric Infectious Diseases, Section Editor of the Pediatric Infectious Diseases Journal (maternal & neonatal), Clinical Lead for Children’s research for South London and a member of the WHO GBS Surveillance Technical Working Group. 

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. 

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group.  

N Engl J Med. 2021 Jun 30:NEJMoa2107659. doi: 10.1056/NEJMoa2107659. 

Listeria infection in young infants: results from a national surveillance study in the UK and Ireland. 

Vergnano S, Godbole G, Simbo A, Smith-Palmer A, Cormican M, Anthony M, Heath PT. Arch Dis Child. 2021 May 13:archdischild-2021-321602. doi: 10.1136/archdischild-2021-321602. 

Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China. 

Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Emerg Infect Dis. 2020 Nov;26(11):2651-2659. doi: 10.3201/eid2611.181414. 

SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes.

Khalil A, Kalafat E, Benlioglu C, O’Brien P, Morris E, Draycott T, Thangaratinam S, Le Doare K, Heath P, Ladhani S, von Dadelszen P, Magee LA. EClinicalMedicine. 2020 Aug;25:100446. doi: 10.1016/j.eclinm.2020.100446. Epub 2020 Jul 3.PMID: 32838230 

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. 

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.PMID: 32702298  

Tatiana (Taty) is the Operations Manager responsible for the strategic planning and overall direction of the group.  She is a group leader with more than 10 years’ experience coordinating and managing a large international portfolio of research studies, including observational studies and phase I-IV adult, maternal, paediatric and neonatal clinical trials funded by national and international agencies and commercial companies. She is a microbiologist by training and joined the PIDRG in 2010 after finishing her PhD in Molecular Biology at Imperial College London.

• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial – PubMed (nih.gov)
• Mutational analysis of the Aspergillus ambient pH receptor PalH underscores its potential as a target for antifungal compounds – PubMed (nih.gov)
• Refining the pH response in Aspergillus nidulans: a modulatory triad involving PacX, a novel zinc binuclear cluster protein – PubMed (nih.gov)
• Further characterization of the signaling proteolysis step in the Aspergillus nidulans pH signal transduction pathway – PubMed (nih.gov)
• Establishment of the ambient pH signaling complex in Aspergillus nidulans: PalI assists plasma membrane localization of PalH – PubMed (nih.gov)

Dr Eva Galiza joined the St. George’s Vaccine Institute (SGVI) in 2006 and has taken part in a wide range of paediatric and adult research work including observational, interventional phase 1-4, CTIMP and non-CTIMPS, and both commercial and non-commercial studies. As the Senior Clinical Research Fellow, Dr Galiza leads and co-ordinates vaccine trials and other infectious diseases studies run by SGVI and the Paediatric Infectious Diseases Research Group (PIDRG), part of the Institute for Infection and Immunity at St. George’s, University of London. She is Principal Investigator for several infectious diseases studies including RSV and coronavirus (COVID-19) vaccine research trials. Currently, Dr Galiza is the lead fellow and coordinator for the Preg-CoV trial looking at COVID-19 vaccines in pregnancy.

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group.

N Engl J Med. 2021 Jun 30:NEJMoa2107659. doi: 10.1056/NEJMoa2107659. Online ahead of print. PMID: 34192426

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T, Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard AJ; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford COVID-19 Vaccine Trial Group.

Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30. PMID: 33798499

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.

Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. PMID: 33617777

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.

Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. PMID: 33306989

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. PMID: 32702298

 

Professor Shamez Ladhani is the clinical lead for a number of national vaccine preventable infections, including Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis, which are all major causes of childhood bacterial meningitis. In the current pandemic, he is the clinical lead for of SARS-CoV-2 in Children.

At St. George’s University of London, he is involved with a number of epidemiological studies and vaccine trials to help inform national immunisation policy. He is published widely in his field, with more than 300 peer-reviewed publications.

1: Mensah AA, Campbell H, Stowe J, Seghezzo G, Simmons R, Lacy J, Bukasa A, O’Boyle S, Ramsay ME, Brown K, Ladhani SN. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. Lancet Child Adolesc Health. 2022 Jun;6(6):384-392.

2: Powell AA, Kirsebom F, Stowe J, McOwat K, Saliba V, Ramsay ME, Lopez-Bernal J, Andrews N, Ladhani SN. Effectiveness of BNT162b2 against COVID-19 in adolescents. Lancet Infect Dis. 2022 May;22(5):581-583.

3: Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, Simmons R, Zavala M, O’Mahoney L, Chalder T, Crawley E, Ford TJ, Harnden A, Heyman I, Swann O, Whittaker E; CLoCk Consortium, Ladhani SN. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health. 2022 Apr;6(4):230-239.

4: Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Thelwall S, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown K, Hopkins S, Chand M, Ladhani SN, Ramsay M, Lopez Bernal J. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022 Jan 27;386(4):340-350. doi: 10.1056/NEJMoa2115481.

5: Dowell AC, Butler MS, Jinks E, Tut G, Lancaster T, Sylla P, Begum J, Bruton R, Pearce H, Verma K, Logan N, Tyson G, Spalkova E, Margielewska-Davies S, Taylor GS, Syrimi E, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, Brent AJ, Brent B, Ireland G, Aiano F, Amin-Chowdhury Z, Jones S, Borrow R, Linley E, Wright J, Azad R, Waiblinger D, Davis C, Thomson EC, Palmarini M, Willett BJ, Barclay WS, Poh J, Amirthalingam G, Brown KE, Ramsay ME, Zuo J, Moss P, Ladhani S. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol. 2022 Jan;23(1):40-49.

6: Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, Ladhani SN. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022 Feb;6(2):96-105. doi: 10.1016/S2352-4642(21)00335-7.

7: Jeffery-Smith A, Burton AR, Lens S, Rees-Spear C, Davies J, Patel M, Gopal R, Muir L, Aiano F, Doores KJ, Chow JY, Ladhani SN, Zambon M, McCoy LE, Maini MK. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost

detectable neutralizing antibodies. J Clin Invest. 2022 Jan 18;132(2):e152042.

8: Subbarao S, Warrener LA, Hoschler K, Perry KR, Shute J, Whitaker H, O’Brien M, Baawuah F, Moss P, Parry H, Ladhani SN, Ramsay ME, Brown KE, Amirthalingam G. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021 Mar;26(12):2100329.

9: Ladhani SN, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, Brent AJ, Brent B, Walker J, Andrews N, Ireland G, Aiano F, Amin-Chowdhury Z, Letley L, Flood J, Jones SEI, Borrow R, Linley E, Zambon M, Poh J, Saliba V, Amirthalingam G, Lopez Bernal J, Brown KE, Ramsay ME. SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study. Lancet Child Adolesc Health. 2021 Jun;5(6):417-427. doi: 10.1016/S2352-4642(21)00061-4.

10: Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hoschler K, Brooks T, Taylor S, Hewson J, Hallis B, Stapley L, Borrow R, Linley E, Ahmad S, Parker B, Horsley A, Amirthalingam G, Brown K, Ramsay ME, Ladhani S, Moss P. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021 May;22(5):620-626.

11: Ismail SA, Saliba V, Lopez Bernal J, Ramsay ME, Ladhani SN. SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England. Lancet Infect Dis. 2021 Mar;21(3):344-353.

12: Gale C, Quigley MA, Placzek A, Knight M, Ladhani S, Draper ES, Sharkey D, Doherty C, Mactier H, Kurinczuk JJ. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance. Lancet Child Adolesc Health. 2021 Feb;5(2):113-121.

13: Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, Seth S, Egan C, Hardwick HE, Halpin S, Girvan M, Donohue C, Pritchard M, Patel LB, Ladhani S, Sigfrid L, Sinha IP, Olliaro PL, Nguyen-Van-Tam JS, Horby PW, Merson L, Carson G, Dunning J, Openshaw PJM, Baillie JK, Harrison EM, Docherty AB, Semple MG; ISARIC4C Investigators. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020 Aug 27;370:m3249.

14: Ladhani SN, Chow JY, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, Fernandez E, Perez MS, Tang S, Dun-Campbell K, Evans EW, Bell A, Patel B, Amin-Chowdhury Z, Aiano F, Paranthaman K, Ma T, Saavedra-Campos M, Myers R, Ellis J, Lackenby A, Gopal R, Patel M, Brown C, Chand M, Brown K, Ramsay ME, Hopkins S, Shetty N, Zambon M. Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. EClinicalMedicine. 2020 Sep;26:100533.

15: Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, Ramsay ME. First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England. Clin Infect Dis. 2021 Oct 5;73(7):e1661-e1668.

16: Lynn RM, Avis JL, Lenton S, Amin-Chowdhury Z, Ladhani SN. Delayed access to care and late presentations in children during the COVID-19 pandemic: a snapshot survey of 4075 paediatricians in the UK and Ireland. Arch Dis Child. 2021 Feb;106(2):e8.

17: Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P. Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia. N Engl J Med. 2020 Jan 23;382(4):318-327.

18: Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med. 2020 Jan 23;382(4):309-317.

Simon Drysdale is a consultant and honorary senior lecturer in paediatric infectious diseases and immunology at St George’s University Hospitals NHS Foundation Trust. He is the paediatric antimicrobial stewardship lead at St George’s and principal investigator on several clinical trials investigating diagnostics, novel treatments and prophylactics for RSV and SARS-CoV-2. His research interests are host susceptibility to RSV and other respiratory viral infections and antimicrobial resistance and stewardship.

1. Drysdale SB, Kelly DF, Morgan M, Peto T, Crook D, Matthews PC, Walker TM. Case Report: Disseminated, rifampicin resistant Mycobacterium bovis (BCG) infection in an immunocompromised child. Wellcome Open Research 2020; 5: 242.
2. Lin GL, Golubchik T, Drysdale S, O’Connor D, Jefferies K, Brown A, de Cesare M, Bonsall D, Ansari MA, Aerssens J, Bont L, Openshaw P, Martinón-Torres F, Bowden R, Pollard AJ. Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. J Infect Dis. 2020 Jul 23:jiaa448. doi: 10.1093/infdis/jiaa448. Online ahead of print.
3. Jefferies K, Drysdale SB, Robinson H, Clutterbuck EA, Blackwell L, McGinley J, Lin GL, Galal U, Nair H, Aerssens J, Öner D, Langedijk A, Bont L, Wildenbeest JG, Martinon-Torres F, Rodríguez-Tenreiro Sánchez C, Nadel S, Openshaw P, Thwaites R, Widjojoatmodjo M, Zhang L, Nguyen TL, Giaquinto C, Giordano G, Baraldi E, Pollard AJ; Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators. Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). J Infect Dis. 2020 Aug 14:jiaa239. doi: 10.1093/infdis/jiaa239. Online ahead of print.
4. Öner D, Drysdale SB, McPherson C, Lin GL, Janet S, Broad J, Pollard AJ, Aerssens J; RESCEU Investigators. Biomarkers for Disease Severity in Children Infected With Respiratory Syncytial Virus: A Systematic Literature Review. J Infect Dis. 2020 Aug 14:jiaa208. doi: 10.1093/infdis/jiaa208. Online ahead of print.
5. Sande CJ, Njunge JM, Mwongeli Ngoi J, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes J, Pollard AJ. Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019;10(1):2218. doi: 10.1038/s41467-019-10222-z.

David is an Infectious Diseases trainee currently undertaking a research placement. Having published work on Vitamin D in latent TB patients and its association with progression to active disease David is now working on a pilot study to increase the sensitivity of TB culture and detect persistent sub-populations of Mycobacteria within patient samples. This pilot data will inform the design of future large clinical trials of these techniques. David has also been working on a number of COVID-19 vaccine trials including leading on the COV001/002 and Valneva trials, and have published editorials on important topics in COVID-19. David previously completed laboratory research on respiratory virus’s effects on the ubiquitin intracellular pathways as part of an intercalated degree at Oxford University.

Smith, D., & Gill, D. (2021). Antivirals against SARS-CoV-2 by autumn?. BMJ, 373, n1215. doi:10.1136/bmj.n1215

Burgess, S., Smith, D., Kenyon, J. C., & Gill, D. (2020). Lightening the viral load to lessen covid-19 severity.. BMJ, 371, m4763. doi:10.1136/bmj.m4763

Patterson, B., Smith, D., Telford, A., Tana, A., Johnstone, D., Davidson, R., & Martineau, A. R. (2020). Vitamin D deficiency predicts latent TB reactivation independent of preventive therapy: a longitudinal study.. Int J Tuberc Lung Dis, 24(9), 916-921. doi:10.5588/ijtld.19.0605

 

Professor Mike Sharland is a globally leading expert in antimicrobial prescribing, resistance and healthcare associated infection in children. He is the lead clinical advisor for the neonatal and paediatric programme of the Global Antibiotic Research and Development Partnership (GARDP) and Vice-Chair and AMR lead of the Penta Foundation, a global Paediatric Infectious Diseases research network.

He has Chaired the Department of Health’s National Expert Advisory Committee of Antimicrobial Prescribing, Resistance and Healthcare Associated Infection (APRHAI) from 2011 to 2018. He has also been an advisor for the WHO for many years, including being a member of the Expert Committee on the Selection and Use of Essential Medicines and the Chair of the Antibiotic Working Group of the EML/EMLc, which developed the Access/Watch/Reserve (AWaRe) grouping of antibiotics.

Prof Sharland’s principal research interest is optimising the best use of antimicrobials in children. He has a long standing interest in developing the evidence base for the use of all paediatric antimicrobials and has developed a clear research strategy using both cohort studies and clinical trials to improve the evidence base for antimicrobial prescribing. He leads a wide number of clinical projects in the globally with active EDCTP, EU H2020, GARDP, NIHR, MRC, Wellcome Trust funding.

The Urgent Need for Simple and Globally Applicable Quality Indicators of Optimal Prescribing for Children Using the Access, Watch, Reserve (AWaRe) System

Daniele Donà, Mike Sharland.

 

Dr Julia Bielicki is a paediatrician and researcher at St George’s, University of London and the University Children’s Hospital Basel, and holds a Master of Public Health and PhD from the London School of Hygiene and Tropical Medicine. She is experienced working in observational and interventional studies that aim to improve paediatric antibiotic use in the light of an increasing burden of antimicrobial resistance and the need to conserve antibiotics for future generations.

She is a member of the Clinical Microbiology and Infection (CMI) editorial board, the Research Board at the University of Basel Children’s Hospital, a Board Member and Assessor of SwissPedNet, Swiss Research Network of Clinical Pediatric Hubs, the Professional Affairs Committee for the European Society for Clinical Microbiology and Infectious Disease (ESCMID) from 2016-2019, the Research Committee on the European Society for Paediatric Infectious Disease (ESPID) from 2014-2017, and the Board of the Children’s Research Centre at the University Children’s Hospital, Zurich, Switzerland from 2012-2014.

Her current research focuses on clinical trials to investigate optimal antibiotic management of childhood pneumonia and neonatal sepsis as well as to identify best practices in neonatal infection prevention and control. She also continues to work on developing appropriate surveillance methodology to assess childhood antibiotic resistance and make surveillance data accessible for clinical practice, particularly in settings where access to additional information relevant for more advanced clinical decision support tools is lacking. She has successfully led a wide number of clinical projects globally with active EDCTP, EU H2020, NIHR, MRC, and Wellcome Trust funding and published over 100 peer reviewed academic papers since 2015, focusing on optimal treatment of severe infections in children.

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial

Julia A. Bielicki, Wolfgang Stöhr, Sam Barratt,; et al.

November 2021 JAMA 326(17):1713 DOI:10.1001/jama.2021.17843

Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT

 

Dr. Catrin Moore’s research focuses on antimicrobial resistance (AMR), often termed the silent pandemic, which is on the increase in many LMICs. Dr. Moore has worked in the Global health arena for over twenty years, she was based in South East Asia running microbiology laboratories for six years. She led the Global Research on AntiMicrobial resistance (GRAM) project in the Big Data Institute in Oxford, partnering with the Institute for Health Metrics and Evaluation (IHME) in Seattle and Tropical Medicine in Oxford, to estimate the global burden of antimicrobial resistance (AMR). Dr Moore is a member of the World Health Organization Advisory Group on Critically Important Antimicrobials (AG CIA) for Human Medicine and is a mentor for Fleming Fund Fellows based in Eswatini. Dr. Moore works on studies to improve the use of diagnostic tools, training, and communication in low- and middle-income countries (LMICs) focussing on implementing interventions and policy to reduce AMR. She is now based at St George’s, University of London working closely with researchers in a number of LMICs, working on the Antimicrobial Resistance, Prescribing, and Consumption Data to Inform Country Antibiotic Guidance and Local Action (ADILA) project.

Murray C, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 2022, Jan; 10.1016/S0140-6736(21)02724-0.

Henry NJ, Elagali A, Nguyen M, Chipeta MG, Moore CE. Variation in excess all-cause mortality by age, sex, and province during the first wave of the COVID-19 pandemic in Italy. Sci Rep, 2022 Jan; 12(1); 1077. Doi: 10.1038/s41598-022-04993-7.

Browne AJ, Chipeta MG, Haines-Woodhouse G, …Moore CE, et al. Global Antibiotic Consumption in Humans, 2000 to 2018: A Spatial Modelling Study. Lancet Planetary Health 2021, Nov 11:S2542-5196(21)00280-1. Doi: 10.1016/S2542-5196(21)00280-1.

Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G, …Moore, CE et al. SARS-CoV-2 within-host diversity and transmission. Science, 2021; 372 (6539) eabg0821. Doi: 10.1126/science.abg0821.

Salami O, Horgan P, Moore CE, Giri A, Sserwanga A et al. Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial. BMC Trials, 2020; 21 (974); 1-13. Doi: 10.1186/s13063-020-04897-9

Basnyat B, Salami O, Karkey A, Moore C, Giri A, Olliaro P. The Impact of Covid-19 on Health Delivery and Research in South East Asia. BMJOpinion (blog). September 2020.

Moore CE. Changes in antibiotic resistance in animals. Perspectives comment invited by Science, 2019. Science. 2019 Sep 20;365(6459):1251-1252. Doi: 10.1126/science.aay9652.

Schnall J, Rajkhowa A, Ikuta K, Rao P, Moore CE. Surveillance and monitoring of antimicrobial resistance: limitations and lessons from the GRAM project. BMC Med. 2019 Sep 20;17(1):176. Doi: 10.1186/s12916-019-1412-8.

Young BC, Earle SG, Soeng S, Sar P, Kumar V, …Moore CE. Panton-Valentine leukocidin is the key determinant of Staphylococcus aureus pyomyositis in a bacterial genome-wide association study. Elife. 2019 Feb 22;8. pii: e42486. Doi: 10.7554/eLife.42486.

Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN,…Moore CE,  et al.; Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC). Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infect Dis. 2019; Aug 16. pii: S1473-3099(19)30276-2. Doi: 10.1016/S1473-3099(19)30276-2.